CERo Therapeutics Holdings, Inc
1.7900-0.09 (-4.79%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · CERO · USD
Key Stats
Market Cap
3.34MP/E (TTM)
-Basic EPS (TTM)
-125.68Dividend Yield
0%Recent Filings
8-K
CERo raises $7M via preferred stock
CERo Therapeutics Holdings entered a securities purchase agreement on October 14, 2025, to issue up to 9,750 shares of Series E convertible preferred stock for $7 million total, starting with $1.8 million at the first closing. This ranks pari passu with Series C and D preferred, convertible to common stock at $4.1625 per share, while reducing prior series conversion prices to $1.76. The deal bolsters liquidity for operations, yet demands stockholder approval by December 31, 2025, to unlock full conversions.
8-K
FDA Fast Track for CER-1236
CERo Therapeutics announced on September 5, 2025, that the FDA granted Fast Track Designation to its lead investigational compound CER-1236 for Acute Myeloid Leukemia, building on its existing Orphan Drug Designation. This milestone accelerates development for the serious condition with unmet needs, enabling more FDA interactions, potential priority review, and rolling data submissions. The ongoing Phase 1/1b trial evaluates safety and efficacy in relapsed/refractory AML patients. Yet risks persist, as actual results may differ from forward-looking expectations.
8-K
Nasdaq delisting threat looms
CERO Therapeutics Holdings faces Nasdaq delisting after failing the $2.5 million stockholders' equity rule on August 28, 2025, just months after regaining compliance in May. The company appealed on September 3, halting suspension until a hearing where it plans to pitch financing to boost equity. Trading hangs in the balance. No guarantees the panel will buy it or that deals will close.
10-Q
Q2 FY2025 results
CERo Therapeutics Holdings posted a Q2 net loss of $5.4 million, up from $2.4 million a year ago, driven by $4.7 million in operating expenses that edged down 8% year-over-year while research and development costs ticked up 1.5% to $2.8 million amid early clinical work on CER-1236. Gross margins aren't applicable yet in this pre-revenue biotech phase, but the company narrowed its operating loss through tighter general and administrative spending, down 19% to $2.0 million. Cash burn remains a drag, with $3.3 million in cash and equivalents at quarter-end funding a Phase 1 AML trial that dosed its second patient in July; free cash flow isn't disclosed in the 10-Q. Recent Series D preferred stock raises bolstered liquidity to $2.2 million net, yet the going concern warning lingers. Clinical progress shines, but regulatory hurdles loom large.
8-K
Series D closing nets $397K
CERo Therapeutics Holdings completed another closing under its Series D preferred stock private placement on July 18, 2025, selling 497 shares to institutional investors for gross proceeds of approximately $397,600. This unregistered offering, exempt under Section 4(a)(2) of the Securities Act, builds on prior tranches totaling over $3 million raised since April. Funds bolster the biotech's cash position amid development efforts. Yet dilution looms upon conversion to common stock.
ALLO
Allogene Therapeutics, Inc.
1.22-0.04
CBIO
Crescent Biopharma, Inc.
12.50+0.00
CLCS
Cell Source, Inc.
0.38+0.03
CPMV
Mosaic ImmunoEngineering Inc.
0.84+0.33
FATE
Fate Therapeutics, Inc.
1.34-0.15
FBLG
FibroBiologics, Inc.
0.39-0.03
IMRX
Immuneering Corporation
6.25-0.24
MAIA
MAIA Biotechnology, Inc.
1.30-0.10
MRKR
Marker Therapeutics, Inc.
0.97-0.04
NBTX
Nanobiotix S.A.
17.99+0.36